BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences:

William Blair's Innovator Series: Genetic Medicines
Nathan Dowden, Chief Operating Officer, will participate on the Changing the Trajectory of Neuromuscular Diseases: DMD and Beyond virtual panel on Monday, October 16, 2023 at 11:00 a.m. Eastern Time.

Evercore ISI 6th Annual HealthCONx Conference
Dipal Doshi, President and Chief Executive Officer, will participate in an in-person fireside chat on Wednesday, November 29, 2023 at 3:50 p.m. Eastern Time in Miami, FL.

A live webcast of the fireside chat at the Evercore ISI 6th Annual HealthCONx Conference and a replay of the panel at William Blair's Innovator Series: Genetic Medicines will be available on the Investor Relations section of the Company’s website at www.entradatx.com. The replay of the fireside chat will be available on the Entrada website for 90 days and the replay of the panel will be available for 7 days following the events.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases, among others. The Company’s lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 44 and 45 skipping amenable, respectively, as well as a partnered candidate ENTR-701 targeting myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor and Media Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com